Please ensure Javascript is enabled for purposes of website accessibility

Why Arcus Biosciences Stock Is Skyrocketing Today

By George Budwell - Apr 16, 2020 at 11:26AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Arcus Biosciences stock is on fire in response to a possible partnership deal with Gilead Sciences.

What happened

Arcus Biosciences, Inc. (RCUS -1.55%), a clinical-stage oncology company, is up big this morning. Specifically, the drugmaker's shares are up by an astounding 84% as of 10:16 a.m. EDT Thursday morning. 

What's sparking this monstrous move higher? In pre-market action, a rumor surfaced that Gilead Sciences (GILD 0.04%) was considering an equity stake in Arcus. This move, if it does indeed come to fruition, would give the biotech heavyweight access to the company's robust, yet fairly early-stage pipeline of unique immuno-oncology assets, such as the anti-TIGIT monoclonal antibody AB154. 

Black and white photo of two businessmen shaking hands over a table.

Image Source: Getty Images.

So what

Not long ago, Gilead Sciences was rumored to have an interest in striking a partnering deal with another clinical-stage biotech company, Forty Seven. A few days later, the two companies announced a $4.9 billion buyout offer. Arcus' shareholders are clearly hoping the same scenario plays out again. After all, the company's new market cap of $1.39 billion might be hard to justify if Gilead and Arcus simply announce a smallish partnering deal for one specific drug candidate. 

Now what

Before investors get too excited, it's important to note that neither company has confirmed these partnering talks. What's more, the unnamed source of this rumor said a deal could still fall apart. Investors shouldn't count their chickens before they hatch. 

On the bright side, Arcus' pipeline would dovetail nicely with Gilead's Kite Pharma subsidiary and its newly acquired assets from Forty Seven. So, in many ways, an Arcus-Gilead pairing does make a lot of sense. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Arcus Biosciences, Inc. Stock Quote
Arcus Biosciences, Inc.
$27.57 (-1.55%) $0.43
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$66.24 (0.04%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.